scholarly journals Sentinel Lymph Node Biopsy Should Be Included with the Initial Surgery for High-Risk Ductal Carcinoma-In-Situ

2014 ◽  
Vol 2014 ◽  
pp. 1-7
Author(s):  
Ern Yu Tan ◽  
Z. W. Joseph Lo ◽  
Chuan Han Ang ◽  
Christine Teo ◽  
Melanie D. W. Seah ◽  
...  

Background. A proportion of those diagnosed preoperatively with ductal carcinoma-in-situ (DCIS) will be histologically upgraded to invasive carcinoma. Repeat surgery for sentinel lymph node (SLN) biopsy will be required if it had not been included with the initial surgery. We reviewed the outcome of SLN biopsy performed with the initial surgery based on a preoperative diagnosis of DCIS and aimed to identify patients at risk of histological upgrade. Methods. Retrospective review of 294 consecutive female patients diagnosed with DCIS was performed at our institute from January 1, 2001, to December 31, 2008. Results. Of the 294 patients, 132 (44.9%) underwent SLN biopsy together with the initial surgery. The SLN was positive for metastases in 5 patients, all of whom had tumours that were histologically upgraded. Histological upgrade also occurred in 43 of the 127 patients (33.9%) in whom the SLN was negative for metastases. On multivariate analysis, histological upgrade was more likely if a mass was detected on mammogram, if the preoperative diagnosis was obtained with core biopsy and if microinvasion was reported in the biopsy. Conclusion. Patients in whom a preoperative diagnosis of DCIS is likely to be upgraded to invasive carcinoma will benefit from SLN biopsy being performed with the initial surgery.

2020 ◽  
Vol 86 (10) ◽  
pp. 1238-1242
Author(s):  
Sonam Kapadia ◽  
Albert Lee ◽  
Amy H. Kaji ◽  
Junko Ozao-Choy ◽  
Christine Dauphine

The upstage rate from ductal carcinoma in situ (DCIS) on core biopsy to invasive carcinoma at definitive excision ranges from 20 to 30%. Nomograms have been developed to aid in the prediction of upstaging so as to guide surgical planning with respect to performance of sentinel lymph node biopsy (SLNB). The aim of this study was to evaluate the ability of these nomograms to predict upstaging within our public hospital population. A retrospective review of patients with DCIS from 2013 to 2018 at a single institution was performed. Individualized probability of upstage was calculated using the Samsung Medical Center (SMC) and Annals of Surgical Oncology (ASO) nomograms. Areas under the receiver operating characteristic curves were calculated to assess the discriminative power of each. Of 105 patients with DCIS, 31 (29.5%) were upstaged to invasive disease. The SMC and ASO nomograms demonstrated area under the curves (AUCs) of .65 (OR = 1.023, 95% CI 1.004-1.042, P = .02) and .60 (OR = 1.035, 95% CI 1.003-1.068, P = .03), respectively. While SMC provided greater discrimination in our cohort, the performance of these nomograms as reliable clinical adjuncts to guide SLNB decision-making in this cohort was less than optimal and thus should not be the sole factor in determining individual upstage risk.


2008 ◽  
Vol 14 (1) ◽  
pp. 55-60 ◽  
Author(s):  
Rita Sakr ◽  
Martine Antoine ◽  
Emmanuel Barranger ◽  
Gil Dubernard ◽  
Christine Salem ◽  
...  

Cancer ◽  
2002 ◽  
Vol 95 (1) ◽  
pp. 15-20 ◽  
Author(s):  
Kelly M. McMasters ◽  
Celia Chao ◽  
Sandra L. Wong ◽  
Robert C. G. Martin ◽  
Michael J. Edwards

2016 ◽  
Vol 23 (7) ◽  
pp. 2229-2234 ◽  
Author(s):  
Melissa Pilewskie ◽  
Maria Karsten ◽  
Julia Radosa ◽  
Anne Eaton ◽  
Tari A. King

2005 ◽  
Vol 190 (4) ◽  
pp. 563-566 ◽  
Author(s):  
Caren Wilkie ◽  
Laura White ◽  
Elisabeth Dupont ◽  
Alan Cantor ◽  
Charles E. Cox

2018 ◽  
Vol 25 (6) ◽  
pp. 1521-1529 ◽  
Author(s):  
Brigid K. Killelea ◽  
Jessica B. Long ◽  
Weixiong Dang ◽  
Sarah S. Mougalian ◽  
Suzanne B. Evans ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document